Is aprocitentan one of the new antihypertensive drugs?

Aprocitentan is a new type of antihypertensive drug that has gradually attracted widespread attention in the field of hypertension treatment in recent years. As an innovative drug, aprecitentan shows unique advantages in pharmacological mechanism and clinical application, and is especially suitable for patients with refractory hypertension for whom conventional antihypertensive treatments are ineffective. This article will introduce in detail the drug characteristics, mechanism of action, clinical value and role of aprecitentan in the treatment of hypertension to help readers fully understand this new antihypertensive drug.

First of all, aprexitentan belongs to the endothelin receptor antagonist (Endothelin receptor antagonist, ERA) class of drugs. Endothelin is a potent vasoconstrictor that plays an important role in blood pressure regulation. Endothelin acts on ETA and ETB receptors on vascular smooth muscle, causing vasoconstriction, thereby increasing blood pressure. Aprecitentan achieves vasodilation and antihypertensive effects by selectively blocking these two receptors and preventing endothelin from binding to the receptors. Compared with traditional antihypertensive drugs such as calcium channel blockers, ACE inhibitors or ARBs, aprecitentan has unique advantages in regulating the endothelin pathway and can effectively alleviate endothelin-mediated vasoconstriction and remodeling, thereby helping to control blood pressure.

Secondly, aprecitentan is particularly suitable for the treatment of patients with refractory hypertension. Refractory hypertension refers to a situation where ideal blood pressure control cannot be achieved despite combined treatment with at least three antihypertensive drugs. Such patients are often associated with higher cardiovascular risks. Aprecitentan helps improve vascular function and reduce vascular resistance through the dual blocking effect of endothelin receptors, thereby further lowering blood pressure. Clinical trial data show that aprecitentan can significantly reduce systolic and diastolic blood pressure in patients with refractory hypertension, and is safe and well tolerated, providing a new treatment option for these patients.
Third, the pharmacokinetic characteristics of aprecitentan also facilitate its clinical application. The drug is well absorbed orally and has a moderate half-life, enabling a once-daily dosing regimen to facilitate patient compliance. In addition, the metabolism pathway of aprecitentan mainly passes through the liver, and its excretion pathways are diverse, making it suitable for patients with different liver and kidney functions. Currently, aprexitentan has not yet been launched in the domestic market. If patients need to use it, they usually need to obtain it through formal overseas channels. The generic versions that are already available overseas are relatively affordable, which helps reduce treatment costs.
Finally, as the understanding of the pathogenesis of hypertension continues to deepen, drugs targeting the endothelin pathway, such as aprecitentan, have high hopes. In the future, as more clinical studies are conducted, aprecitentan is expected to gain wider recognition and application worldwide. For patients, aprecitentan not only provides a new antihypertensive solution, but also opens up new ideas for comprehensive management of hypertension. When formulating treatment plans, medical staff should reasonably evaluate the application value of aprecitentan based on the patient's individual characteristics and condition to achieve precise treatment.
To sum up, aprecitentan is indeed one of the new antihypertensive drugs. Through its unique endothelin receptor antagonism mechanism, it is especially suitable for patients with refractory hypertension, injecting new vitality into the field of hypertension treatment. With the promotion of the drug and the deepening of clinical application, aprecitentan is expected to become an important choice for patients with hypertension, especially those who are ineffective with traditional treatments.
Reference: https://go.drugbank.com/drugs/DB15059